Alterations in the Oral and Gut Microbiome of Colorectal Cancer Patients and Association with Host Clinical Factors

Author(s):  
Yao Wang ◽  
Yao Zhang ◽  
Yun Qian ◽  
Yuan‐Hong Xie ◽  
Shan‐Shan Jiang ◽  
...  
2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
C Li ◽  
S Z Y Ooi ◽  
T Woo ◽  
P H M Chan

Abstract Aim To identify the most relevant clinical factors in the National Bowel Cancer Audit (NBOCA) that contribute to the variation in the quality of care provided in different hospitals for colorectal cancer patients undergoing surgery. Method Data from 36,116 patients with colorectal cancer who had undergone surgery were retrospectively collected from the NBOCA and analysed from 145 and 146 hospitals over two years. A validated multiple linear regression was performed to compare the identified clinical factors with various quality outcomes. The quality outcomes defined in this study were the length of hospitalisation, 2-year mortality, readmission rate, 90-day mortality, and 18-month stoma rate. Results Four clinical factors (laparoscopy rate, abdominal-perineal-resection-of-rectum (APER), pre-operative radiotherapy and patients with distant metastases) were shown to have a significant (p < 0.05) impact on the length of hospitalisation and 18-month stoma rate. 18-month stoma rate was also significantly associated with 2-year mortality. External validation of the regression model demonstrated the Root-Mean-Square-Error of 0.811 and 4.62 for 18-month stoma rate and 2-year mortality respectively. Conclusions Hospitals should monitor the four clinical factors for patients with colorectal cancer during perioperative care. Clinicians should consider these factors along with the individual patients’ history when formulating a management plan for patients with colorectal cancer.


2015 ◽  
Vol 20 (2) ◽  
pp. 127-133 ◽  
Author(s):  
Scott Kopetz ◽  
Josep Tabernero ◽  
Robert Rosenberg ◽  
Zhi‐Qin Jiang ◽  
Víctor Moreno ◽  
...  

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 591-591
Author(s):  
Michela Del Prete ◽  
Riccardo Giampieri ◽  
Fotios Loupakis ◽  
Tiziana Prochilo ◽  
Lisa Salvatore ◽  
...  

591 Background: Most of the patients receiving regorafenib do not seem to benefit from this treatment approach and are therefore exposed to unnecessary toxicity. Angiogenesis and inflammation-related factors may have a relevant role in modulating the activity of anti-angiogenetic drugs such as regorafenib. In our study, we investigated LDH serum levels, platelet, neutrophil, and lymphocyte counts, and neutrophil-to-lymphocyte ratio (NLR) in predicting clinical outcomes for colorectal cancer patients receiving regorafenib. The final aim was to individuate an easy to use and reliable selection tool for these patients in the clinical practice. Methods: We collected LDH serum levels, neutrophil, lymphocyte, and platelet counts within one month before the start of regorafenib in 208 pretreated metastatic colorectal cancer patients. Cut-off values were calculated by ROC curve analysis. Survival analysis was performed by Kaplan-Meier method, and multivariate analysis by Cox method. Results: At multivariate analysis: high platelet count (p=0.0439), low lymphocyte count (p=0.0013), and high NLR (p=0.0237) were related to worse overall survival (OS); high neutrophil count and high NLR (p=0.0058) were related to worse progression free survival (PFS). Among 52 (25%) patients who were negative for all risk factors, a significant correlation was found with improved OS and PFS if compared with the group of patients with at least one risk factor. In particular, median OS was respectively 15.9 vs. 3.1 months (HR: 3.81, 95% CI: 2.32-4.82, p<0.0001) whereas median PFS was 5.9 vs. 2.1 months (HR: 2.62, 95% CI: 2.06-3.86, p<0.0001). Conclusions: We can speculate that colorectal cancer patients showing high neutrophil, high platelet, low lymphocyte count or high NLR may not be optimal candidates for regorafenib treatment. After confirmation in further prospective series, these clinical factors could play a role in the treatment strategy process.


Author(s):  
Friederike Schlueter ◽  
Katharina Doetzer ◽  
Martin Pruefer ◽  
Alexandr V. Bazhin ◽  
Jens Werner ◽  
...  

2018 ◽  
Vol 207 (3-4) ◽  
pp. 211-225 ◽  
Author(s):  
Imane Allali ◽  
Noureddine Boukhatem ◽  
Leila Bouguenouch ◽  
Hanaa Hardi ◽  
H. Abir Boudouaya ◽  
...  

eLife ◽  
2020 ◽  
Vol 9 ◽  
Author(s):  
Tarini S Ghosh ◽  
Mrinmoy Das ◽  
Ian B Jeffery ◽  
Paul W O'Toole

Interaction between disease-microbiome associations and ageing has not been explored in detail. Here, using age/region-matched sub-sets, we analysed the gut microbiome differences across five major diseases in a multi-cohort dataset constituting more than 2500 individuals from 20 to 89 years old. We show that disease-microbiome associations display specific age-centric trends. Ageing-associated microbiome alterations towards a disease-like configuration occur in colorectal cancer patients, thereby masking disease signatures. We identified a microbiome disease response shared across multiple diseases in elderly subjects that is distinct from that in young/middle-aged individuals, but also a novel set of taxa consistently gained in disease across all age groups. A subset of these taxa was associated with increased frailty in subjects from the ELDERMET cohort. The relevant taxa differentially encode specific functions that are known to have disease associations.


Oncotarget ◽  
2015 ◽  
Vol 6 (32) ◽  
pp. 33982-33992 ◽  
Author(s):  
Michela Del Prete ◽  
Riccardo Giampieri ◽  
Fotios Loupakis ◽  
Tiziana Prochilo ◽  
Lisa Salvatore ◽  
...  

2018 ◽  
Vol 37 (11) ◽  
pp. 1015-1024
Author(s):  
Fabiola Müller ◽  
Marrit A. Tuinman ◽  
Ellen Stephenson ◽  
Ans Smink ◽  
Anita DeLongis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document